Voriconazole

Generic Name: Voriconazole

Brand Names: Vfend, Voriconazole Hikma (previously Voriconazole Hospira), Voriconazole Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₄F_₃N_₅O

CAS Number: 137234-62-9

Unique Ingredient Identifier: JFU09I87TR

Background: Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha ...

Indication: For the treatment of esophageal candidiasis, cadidemia, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp.

Associated Conditions: Aspergillosis of the Central Nervous System, Aspergillosis of the Liver, Candidemia, Candidiasis, Coccidioidomycosis, Endocarditis caused by Aspergillus, Esophageal Candidiasis, Fungal Infections, Fungal meningitis caused by Exserohilum Infection, Fusarium infection, Histoplasmosis, Invasive Aspergillosis, Osteomyelitis caused by Aspergillus, Penicillium marneffei infection, Peritonitis caused by Aspergillus, Scedosporium Infection, Sinusitis aspergillus, Aspergillus endophthalmitis, Refractory Oral Candidiasis

Associated Therapies: -

Clinical Trials

A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity

Phase 1

Completed

Conditions: Healthy Volunteers
Fungal Infections
Bacterial Infections

Interventions: Drug: Voriconazole
Drug: Doxycycline

First Posted Date: 2006-07-17

Last Posted Date: 2024-12-19

Lead Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Target Recruit Count: 62

Registration Number: NCT00353158

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

To Determine The Amount Of Voriconazole In The Brain After 2 Loading Doses And 3 Maintenance Doses Over 3 Days

Phase 4

Completed

Conditions: Infections, Fungal

Interventions: Drug: voriconazole

First Posted Date: 2006-03-09

Last Posted Date: 2009-10-14

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT00300677

Locations: 🇺🇸
Pfizer Investigational Site, Belmont, Massachusetts, United States

A Study To Assess The Efficacy And Safety Of Voriconazole In Chinese Patients With Serious Deep Tissue Fungal Infections

Phase 4

Completed

Conditions: Invasive Fungal Infections

First Posted Date: 2006-02-07

Last Posted Date: 2008-06-12

Lead Sponsor: Pfizer

Target Recruit Count: 77

Registration Number: NCT00288197

Locations: 🇨🇳
Pfizer Investigational Site, Tianjin, China

Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems

Phase 2

Terminated

Conditions: Infection
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: caspofungin acetate
Drug: voriconazole

First Posted Date: 2005-10-13

Last Posted Date: 2011-12-19

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 13

Registration Number: NCT00238355

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Children

Phase 1

Completed

Conditions: Neutropenia

First Posted Date: 2005-09-15

Last Posted Date: 2011-05-10

Lead Sponsor: Pfizer

Target Recruit Count: 49

Registration Number: NCT00174473

Voriconazole For Chronic Bronchopulmonary Aspergillosis

Phase 2

Completed

Conditions: Aspergillosis

Interventions: Drug: Voriconazole

First Posted Date: 2005-09-12

Last Posted Date: 2010-01-20

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT00159822

Locations: 🇫🇷
Pfizer Investigational Site, Suresnes, France

Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia

Phase 3

Terminated

Conditions: Leukemia, Myelocytic, Acute

First Posted Date: 2005-09-09

Last Posted Date: 2006-11-14

Lead Sponsor: University of Cologne

Target Recruit Count: 150

Registration Number: NCT00152594

Locations: 🇩🇪
Johann Wolfgang Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany
🇩🇪
Universitätsklinikum Mannheim, Universität Heidelberg, Heidelberg, Germany
🇩🇪
Klinikum der Universität Köln, Köln, Germany

Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants

Phase 4

Completed

Conditions: Prophylaxis Of Invasive Fungal Infections

Interventions: Drug: voriconazole

First Posted Date: 2005-09-02

Last Posted Date: 2009-10-06

Lead Sponsor: Pfizer

Target Recruit Count: 45

Registration Number: NCT00143312

Locations: 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom

Assessment of Voriconazole Penetration Into the Brain by Fluorine-Magnetic Resonance Spectroscopy

Phase 1

Completed

Conditions: Fungal Infection

First Posted Date: 2005-08-29

Last Posted Date: 2009-03-12

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT00136968

Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis

Phase 3

Completed

Conditions: Infection
Pulmonary Complications

First Posted Date: 2004-05-27

Last Posted Date: 2012-07-02

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 212

Registration Number: NCT00003031

Locations: 🇦🇺
St. Vincent's Hospital, Sydney, New South Wales, Australia
🇬🇧
King's College Hospital, London, England, United Kingdom
🇪🇸
Hospital de Cruces, Barakaldo, Bilbao, Spain

and more 71 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy